You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

166 Results
Document
May 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
EPIrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Document
New
Nov 2025
Document
New
Nov 2025
Document
New
Nov 2025
Document
New
Nov 2025
Document
New
Nov 2025
Document
New
Nov 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
DACTINomycin,
etoposide,
methotrexate,
leucovorin,
cyclophosphamide,
vinCRIStine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
PACLitaxel,
CISplatin,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
etoposide,
CISplatin,
methotrexate,
leucovorin,
DACTINomycin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
ODB - General Benefit
    exemestane
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
exemestane,
ribociclib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
New
Dec 2025

Pages